Thyroid Cancer Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 12, 2018--The “Thyroid Cancer - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Thyroid Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 35, 24, 3, 17 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively.
Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Thyroid Cancer - Overview Thyroid Cancer - Therapeutics Development Thyroid Cancer - Therapeutics Assessment Thyroid Cancer - Companies Involved in Therapeutics Development Thyroid Cancer - Drug Profiles Thyroid Cancer - Dormant Projects Thyroid Cancer - Discontinued Products Thyroid Cancer - Product Development Milestones Appendix
Companies MentionedAbbVie Inc Advenchen Laboratories LLC Bayer AG Blueprint Medicines Corp Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Celgene Corp Celldex Therapeutics Inc Centrose LLC CSPC Pharmaceutical Group Limited Curis Inc CytImmune Sciences Inc Cytori Therapeutics Inc Eisai Co Ltd Ensol Biosciences Inc Exelixis Inc F. Hoffmann-La Roche Ltd Genelux Corp Genmab A/S Gradalis Inc Hutchison MediPharma Ltd Immunomedics Inc Johnson & Johnson Konruns Pharmaceutical Co Ltd Merck & Co Inc Mersana Therapeutics Inc Millennium Pharmaceuticals Inc Novartis AG Ono Pharmaceutical Co Ltd Pfizer Inc Plexxikon Inc Rodos BioTarget GmbH Tarveda Therapeutics Inc Vascular Biogenics Ltd Xspray Pharma AB
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/x44hpp/thyroid_cancer?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181012005116/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs ,Thyroid Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 10/12/2018 05:13 AM/DISC: 10/12/2018 05:13 AM